0001171843-22-007635.txt : 20221122
0001171843-22-007635.hdr.sgml : 20221122
20221122161549
ACCESSION NUMBER: 0001171843-22-007635
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221118
FILED AS OF DATE: 20221122
DATE AS OF CHANGE: 20221122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bisker-Leib Vered
CENTRAL INDEX KEY: 0001814093
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39696
FILM NUMBER: 221410552
MAIL ADDRESS:
STREET 1: C/O COMPASS
STREET 2: 245 FIRST STREET, 3RD FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Compass Therapeutics, Inc.
CENTRAL INDEX KEY: 0001738021
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
BUSINESS PHONE: 617-500-8099
MAIL ADDRESS:
STREET 1: 80 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
FORMER COMPANY:
FORMER CONFORMED NAME: Olivia Ventures, Inc.
DATE OF NAME CHANGE: 20180419
4
1
ownership.xml
X0306
4
2022-11-18
0
0001738021
Compass Therapeutics, Inc.
CMPX
0001814093
Bisker-Leib Vered
C/O COMPASS THERAPEUTICS, INC.
80 GUEST ST., SUITE 601
BOSTON
MA
02135
0
1
0
0
Chief Operating Officer
Common Stock
2022-11-18
4
S
0
6226
4.40
D
1107175
D
Common Stock
2022-11-21
4
S
0
16035
4.34
D
1084914
D
The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.
The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.49 per share on November 18, 2022 and $4.30 to $4.44 on November 21, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.
/s/ Vered Bisker-Leib
2022-11-22